XASX
CU6
Market cap509mUSD
Oct 09, Last price
1.85AUD
1D
-5.61%
1Q
-23.24%
IPO
102.19%
Name
Clarity Pharmaceuticals Ltd
Chart & performance
P/E
—
P/S
—
EPS
—
Div yield, %
—
Shrs. gr., 5y
7.45%
Rev. gr., 5y
27.68%
Revenues
0
-100.00%
Net income
-107m
L+66.64%
CFO
-93m
L+68.98%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, engages in research and development of radiopharmaceuticals products for oncology in Australia and the United States. The company’s lead product is SAR-bisPSMA, a theranostic radiopharmaceutical for the treatment of Prostate Specific Membrane Antigen (PSMA) cancer. It also develops SAR-Bombesin, a pan cancer theranostic radiopharmaceutical to treat prostate, breast, ovarian, urinary, small cell lung cancer, as well as glioblastoma and gastrointestinal stromal tumours; and SARTATE, a theranostic radiopharmaceutical for the treatment of somatostatin receptor 2 (SSTR2) cancer. The company was incorporated in 2010 and is based in Sydney, Australia.
Key people
David Green
Chief Financial Officer · since 2022
Colin Biggin
Chief Operating Officer, Executive Director · since 2024
Matthew Harris
Chief Scientific Officer · since 2024
Eva Lengyelova
Vice President - Clinical Development · since 2024
Michelle Parker
Chief Executive Officer, Managing Director, Executive Director · since 2024
Alan Taylor
Executive Chairman of the Board · since 2013
Othon Gervasio
Chief Medical Officer · since 2023
Robert Vickery
Company Secretary · since 2022
Rosanne Robinson
Lead Independent Non-Executive Director · since 2024
Thomas Ramdahl
Non-Executive Director · since 2019
Christopher Roberts
Non-Executive Director · since 2016
IPO date
Aug 25, 2021
Employees
41
Domiciled in
AU
Incorporated in
AU
Valuation
Title AUD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2026‑06 | 2025‑06 | 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||